(1.30%) 5 130.09 points
(1.18%) 38 677 points
(2.04%) 16 164 points
(-1.08%) $78.10
(5.85%) $2.15
(-0.13%) $2 306.60
(-0.49%) $26.70
(0.32%) $965.65
(-0.37%) $0.929
(-1.24%) $10.86
(-0.13%) $0.797
(0.39%) $91.49
0.56% $ 5.37
@ $6.07
Wydano: 13 vas. 2024 @ 22:46
Zwrot: -11.53%
Poprzedni sygnał: vas. 13 - 16:30
Poprzedni sygnał:
Zwrot: -2.10 %
Live Chart Being Loaded With Signals
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 163 940 |
Średni wolumen | 644 527 |
Kapitalizacja rynkowa | 517.59M |
EPS | $-0.490 ( 2024-05-02 ) |
Następna data zysków | ( $-0.510 ) 2024-06-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.44 |
ATR14 | $0.00900 (0.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-30 | Polaris Venture Management Co. Vi, L.l.c. | Sell | 500 000 | Common Stock |
2024-04-30 | Polaris Venture Management Co. Vi, L.l.c. | Buy | 98 533 | Common Stock |
2024-04-30 | Polaris Venture Management Co. Vi, L.l.c. | Sell | 98 533 | Common Stock |
2024-03-19 | Altmeyer Mark | Buy | 41 250 | Common Stock |
2024-03-19 | Altmeyer Mark | Buy | 19 420 | Stock Option (right to buy) |
INSIDER POWER |
---|
-25.32 |
Last 100 transactions |
Buy: 2 784 515 | Sell: 4 159 752 |
Wolumen Korelacja
Alector Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
INGN | 0.946 |
UEIC | 0.946 |
SPTN | 0.942 |
NKTR | 0.94 |
SSP | 0.938 |
TUEM | 0.931 |
AADI | 0.931 |
MQ | 0.929 |
GBNH | 0.928 |
BAND | 0.927 |
10 Najbardziej negatywne korelacje | |
---|---|
XLRN | -0.935 |
ALR | -0.917 |
ORTX | -0.917 |
FLMN | -0.917 |
CPTA | -0.916 |
TYHT | -0.911 |
HILS | -0.91 |
MYRG | -0.909 |
INOD | -0.909 |
RESN | -0.906 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Alector Inc Korelacja - Waluta/Towar
Alector Inc Finanse
Annual | 2023 |
Przychody: | $97.06M |
Zysk brutto: | $88.21M (90.88 %) |
EPS: | $-1.560 |
FY | 2023 |
Przychody: | $97.06M |
Zysk brutto: | $88.21M (90.88 %) |
EPS: | $-1.560 |
FY | 2022 |
Przychody: | $133.62M |
Zysk brutto: | $125.15M (93.66 %) |
EPS: | $-1.620 |
FY | 2021 |
Przychody: | $207.09M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.467 |
Financial Reports:
No articles found.
Alector Inc
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej